SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced the closing of an oversubscribed $50 million extension to its Series B financing. The Series B extension was led by new investors Mubadala Capital and Exor Ventures, with participation from Qatar Investment Authority (QIA), and existing investors Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners..

圣地亚哥--（商业新闻短讯）--Iambic Therapeutics是一家临床阶段的生物技术公司，使用其独特的人工智能驱动的发现平台开发新型疗法，今天宣布结束其B系列融资的5000万美元超额认购延期。。。

The extension adds to an oversubscribed $100 million Series B that closed in October and was co-led by Ascenta Capital and Abingworth and joined by NVIDIA and others.

此次延期增加了超额认购的一亿美元B系列，该系列于10月结束，由Ascenta Capital和Abingworth共同领导，NVIDIA和其他公司加入。

Proceeds from the latest financing will be used to further Iambic’s pipeline of clinical and pre-clinical programs. These include IAM1363, a highly selective, brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1/1b study, as well as a potential first-in-class selective dual CDK2/4 inhibitor designed to expand the therapeutic window and address treatment resistance in solid tumors in diseases such as breast cancer..

最新融资的收益将用于进一步推进Iambic的临床和临床前计划。这些包括IAM1363，一种目前正在进行1/1b期研究的野生型和致癌HER2突变体的高选择性脑渗透性小分子抑制剂，以及一种潜在的一流选择性双CDK2/4抑制剂，旨在扩大治疗窗口并解决乳腺癌等疾病实体瘤的治疗耐药性。。

“We are delighted to build this strong team of investors around the company who share our conviction in the demonstrated power of the Iambic AI-driven technology platform to deliver highly differentiated drugs to the clinic,” said Iambic’s Chief Executive Officer Thomas Miller, Ph.D.

Iambic首席执行官Thomas Miller博士说：“我们很高兴在公司周围建立起强大的投资者团队，他们与我们一样相信Iambic AI驱动的技术平台在向诊所提供高度分化的药物方面所表现出的强大力量。”。

Iambic’s pipeline candidates were discovered using its leading AI models for protein structure prediction and wholistic drug design. These technologies are integrated within a closed-loop, automated, high-throughput biology and chemistry experimental platform that provides new biological insights from thousands of molecular designs each week, which in turn directly inform its AI models..

Iambic的候选管道是使用其领先的AI模型发现的，用于蛋白质结构预测和整体药物设计。这些技术集成在一个闭环，自动化，高通量的生物学和化学实验平台中，该平台每周从数千个分子设计中提供新的生物学见解，进而直接为其AI模型提供信息。。

“Iambic is a true innovator, both in the demonstrated accuracy and speed of its state-of-the art AI drug discovery models, and its ability to rapidly advance candidates from discovery and into human studies,” said Ayman AlAbdallah, Partner at Mubadala Capital. “Iambic is a company purpose-built for AI and drug discovery and we are excited to see how their machine learning and drug hunting expertise will help deliver on the promise of AI to bring potential life-saving medicines to patients.”.

穆巴达拉资本（Mubadala Capital）合伙人艾曼·阿拉巴达拉（AymanAlabdalah）表示：“Iambic是一个真正的创新者，无论是在其最先进的人工智能药物发现模型的准确性和速度方面，还是在将候选人从发现快速推进人体研究方面，都是如此。”。“Iambic是一家专门为人工智能和药物发现而创建的公司，我们很高兴看到他们的机器学习和药物搜索专业知识将如何帮助实现人工智能的承诺，为患者带来潜在的救生药物。”。

About the Iambic Therapeutics Physics-Informed AI-Driven Discovery Platform

关于Iambic Therapeutics物理信息人工智能驱动的发现平台

The Iambic Therapeutics AI-driven platform was created to address the most challenging design problems in drug discovery, incorporating the most current AI technologies and purpose-built tools from Iambic. The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures.

Iambic Therapeutics AI驱动平台是为了解决药物发现中最具挑战性的设计问题而创建的，它结合了Iambic最新的AI技术和专门构建的工具。将物理原理集成到平台的AI架构中可以提高数据效率，并允许分子模型在可能的化学结构空间中广泛冒险。

The platform’s algorithms enable identification of new chemical mechanisms for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and exploration of the chemical space to discover candidates for development with highly differentiated properties.

该平台的算法能够识别新的化学机制，以参与难以解决的生物靶标，发现优化治疗窗口的定义产品概况，以及探索化学空间以发现具有高度分化特性的开发候选者。

Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence..

通过将人工智能生成的分子设计与自动实验执行紧密结合，Iambic以每周的节奏完成设计-制作-测试周期。。

About Iambic Therapeutics

关于抑扬格疗法

Founded in 2019 and headquartered in San Diego, California, Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics.

Iambic Therapeutics成立于2019年，总部位于加利福尼亚州圣地亚哥，凭借其独特的人工智能驱动的药物发现平台，正在颠覆治疗学的格局。Iambic组建了一个世界级的团队，该团队将领先的人工智能专家和经验丰富的药物猎手团结在一起，在提供临床验证治疗方面取得了良好的成功记录。

The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs.

Iambic平台已被证明可以以前所未有的速度，跨多个目标类别和作用机制，为临床阶段提供高质量，差异化的治疗方法。Iambic团队正在推进临床资产的内部管道，以解决紧急未满足的患者需求。

Learn more about the Iambic team, platform, and pipeline at iambic.ai..

在Iambic.ai了解更多关于Iambic团队、平台和管道的信息。。